LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
Autor: | S.M. Lee, C. Schulz, K. Prabhash, B. Han, A. Szczesna, D.L. Cortinovis, A. Rittmeyer, D. Vicente Baz, R. Califano, L. Tuan Anh, G. Liu, F. Cappuzzo, J.G. Reyes Contreras, M. Reck, Y. Hu, S. Morris, E.K. Hoeglander, M. Connors, H.K.M. Vollan, S. Peters |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Annals of Oncology. 33:S1418-S1419 |
ISSN: | 0923-7534 |
Databáze: | OpenAIRE |
Externí odkaz: |